Advanced search
Publication Cover
Biologics: Targets and Therapy Volume 12, 2018 - Issue
Submit an article Journal homepage
77
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Yusuf Yazici1 Rheumatology, New York University, School of Medicine, New York, NY, USA
,
Lin Xie2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]
,
Adesuwa Ogbomo2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]Correspondence[email protected]
,
Lorie A Ellis3 Real World Value and Evidence, Janssen Scientific Affairs, Titusville, NJ, USA
,
Kavitha Goyal4 Immunology Medical Affairs, Janssen Biotech Incorporated, Horsham, PA, USA
,
Amanda Teeple5 Health Economics and Outcomes Research, Jassen Scientific Affairs, LLC, Horsham, PA, USA
&
Ismail Simsek6 Department of Rheumatology, Guven Hospital, Ankara, Turkey
 show all
Pages 127-134 | Published online: 25 Oct 2018

References

  • Ben-HorinSYavzoriMBenharICross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar RemsimaGut20166571132113825897019
  • BlairHADeeksEDInfliximab biosimilar (CT-P13; Infliximab-dyyb): a review in autoimmune inflammatory diseasesBioDrugs201630546948027650650
  • JhaAUptonADunlopWCAkehurstRThe budget impact of bio-similar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countriesAdv Ther201532874275626343027
  • GaBI Online [webpage on the Internet]Biosimilar Infliximab Receives Approval in Japan and Turkey2014 Available from: http://www.gabi-online.net/Biosimilars/News/Biosimilar-infliximab-receives-approval-in-Japan-and-TurkeyAccessed September 17, 2015
  • Food and Drug AdministrationGuidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Draft Guidance)2012 Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdfAccessed February 6, 2018
  • KangYSMoonHHLeeSELimYJKangHWClinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case seriesDig Dis Sci201560495195625326115
  • BaserOBaserEAltinbasABurkanASeverity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in TurkeyHealth Econ Rev201331523497510
  • BaserOBurkanABaserEKoselerliRErtugayEAltinbasADirect medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims DatabaseRheumatol Int201333102577258423708559
  • PsatyBMHeckbertSRKoepsellTDThe risk of myocardial infarction associated with antihypertensive drug therapiesJAMA199527486206257637142
  • García RodríguezLAJickHRisk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugsLancet199434389007697727907735
  • AvouacJMoltóAAbitbolVSystematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, FranceSemin Arthritis Rheum2018475S0049304365 Epub ahead of print
  • TweehuysenLvan den BemtBJFvan IngenILSubjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar InfliximabArthritis Rheumatol2018701606829045077
  • GlintborgBSørensenIJLoftAGA nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnn Rheum Dis20177681426143128473425
  • ParkWYooDHMirandaPEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyAnn Rheum Dis201776234635427117698
  • YooDHProdanovicNJaworskiJEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnn Rheum Dis201776235536327130908
  • JørgensenKKOlsenICGollGLSwitching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialLancet2017389100862304231628502609
  • LeopoldCHablCVoglerSTendering of Pharmaceuticals in EU Member States and EEA CountriesResults from the Country SurveyViennaÖBIG Forschungsund Planungs GesmbH2008 Available from: https://ppri.goeg.at/Downloads/Publications/Final_Report_Tendering_June_08.pdfAccessed July 1, 2018
  • TweehuysenLvan den BemtBJFvan IngenILSubjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition from Reference Infliximab to Biosimilar InfliximabArthritis Rheumatol2018701606829045077
  • GlintborgBSorensenIJLoftAGA nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnn Rheum Dis20177681426143128473425

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.